A blog about children’s cancer survivors, fighters and supporters,
and the cancer research that accelerates the search for cures.
CureSearch is pleased to announce the appointment of John Polson, Chairman and Managing Partner of Fisher Phillips, to our Board of Directors.
CureSearch for Children’s Cancer Welcomes John Polson to Board of Directors Read More »
We’re thrilled to celebrate Frank Gioscia, a longtime Ultimate Hike champion, who has officially surpassed $500,000 in lifetime fundraising—a milestone that makes him Ultimate Hike’s top fundraiser of all time!
Ultimate Hiker Frank Gioscia raises $500K for Childhood Cancer Research Read More »
For most families, childhood cancer is unfathomable. But for families like Luke Getchell’s, childhood cancer is their heartbreaking, stomach-turning reality. In July of 2018, 13-year-old Luke was diagnosed with acute myeloid leukemia (AML) with a common genetic alteration, FLT3-ITD. That
Today, we’re announcing $2M in funding for a new pediatric brain cancer clinical trial. Dr. Mohamed Abdelbaki’s team is testing a new type of cancer immunotherapy in children with recurrent brain tumors, with funding from a CureSearch Catapult Award. August
We’re partnering internationally to create far-reaching impact for kids with cancer We’re excited to share news of our recent partnership with LifeArc, a highly-regarded UK-based medical research charity. LifeArc will co-fund Dr. Gregory Friedman’s CureSearch Acceleration Initiative (AI) project aimed
CureSearch and UK-based LifeArc to Co-fund Nearly $1.5M in High-grade Glioma Research Read More »
The prognosis for metastatic Ewing sarcoma can be devastating. Dr. Lee’s research may change that. Ewing sarcoma (ES) is a bone cancer that can be difficult to treat once it has spread. The 5-year survival rate for children with the
Dr. Lee’s Mission: A Promising Future for Children with Advanced Ewing Sarcoma Read More »
Pediatric low-grade glioma (pLGG) is the most common form of pediatric brain cancer. Day One’s OJEMDA™ is the first targeted treatment for pLGG tumors with BRAF fusions and mutations. Last week, on April 23, 2024, Day One Biopharmaceuticals was granted Accelerated
The urgent need for advanced childhood brain cancer research G34R-mutant pediatric diffuse glioma, a devastating brain cancer affecting children and young adults, poses significant challenges in treatment due to its aggressive nature, limited therapeutic options, and the long-term side effects.
This Pediatric Glioma has no known cure. Dr. Breunig is Taking on the Challenge. Read More »
Neuroblastoma is the most common extracranial solid tumor of childhood arising within the developing nervous system. Approximately half of neuroblastoma patients are diagnosed with high-risk disease, which is especially aggressive with a 50% survival rate. If a child’s high-risk neuroblastoma
Acute Myeloid leukemia (AML) is the second most common leukemia in children, and the prognosis after relapse is poor. Unlike current CAR T treatment for the most common childhood leukemia, acute lymphoblastic leukemia (ALL), patients with AML experience significant toxicity
Dr. Moghimi is developing next-generation CAR T-cells to treat pediatric AML. Read More »
